UNLABELLED: Itraconazole is currently used for the treatment of cutaneous sporotrichosis. Terbinafine at a daily dose of 250 mg has been successfully applied to the treatment of cutaneous sporotrichosis. OBJECTIVE: To compare the efficacy of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. MATERIALS AND METHODS: A bidirectional cohort study was conducted on 55 patients receiving 250 mg/dayterbinafineand 249 patients receiving 100 mg/dayitraconazole. The latter patients were matched for age and clinical form to the terbinafine group at a ratio of 5:1. Sporothrix schenckii was isolated by culture from all patients (age range: 18-70 years), who were submitted to the standard care protocol consisting of clinical and laboratory evaluation and periodic visits. RESULTS:Cure was observed in 51 (92.7%) patients of the terbinafine group and 229 (92%) of the itraconazole group within a similar mean period of time (11.5 and 11.8 weeks, respectively). An increase in the terbinafine dose to 500 mg was necessary in two patients due to the lack of a response, and one patient presented recurrence. In the itraconazole group, two patients required a dose increase and three presented recurrence. Adverse events were equally frequent among patients receiving terbinafine (n = 4, 7.3%) and itraconazole (n = 19, 7.6%) and were generally mild without the need for drug discontinuation, except for two patients of the itraconazole group. CONCLUSION:Terbinafine administered at a daily dose of 250 mg is an effective and well-tolerated option for the treatment of cutaneous sporotrichosis.
RCT Entities:
UNLABELLED: Itraconazole is currently used for the treatment of cutaneous sporotrichosis. Terbinafine at a daily dose of 250 mg has been successfully applied to the treatment of cutaneous sporotrichosis. OBJECTIVE: To compare the efficacy of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. MATERIALS AND METHODS: A bidirectional cohort study was conducted on 55 patients receiving 250 mg/day terbinafine and 249 patients receiving 100 mg/day itraconazole. The latter patients were matched for age and clinical form to the terbinafine group at a ratio of 5:1. Sporothrix schenckii was isolated by culture from all patients (age range: 18-70 years), who were submitted to the standard care protocol consisting of clinical and laboratory evaluation and periodic visits. RESULTS: Cure was observed in 51 (92.7%) patients of the terbinafine group and 229 (92%) of the itraconazole group within a similar mean period of time (11.5 and 11.8 weeks, respectively). An increase in the terbinafine dose to 500 mg was necessary in two patients due to the lack of a response, and one patient presented recurrence. In the itraconazole group, two patients required a dose increase and three presented recurrence. Adverse events were equally frequent among patients receiving terbinafine (n = 4, 7.3%) and itraconazole (n = 19, 7.6%) and were generally mild without the need for drug discontinuation, except for two patients of the itraconazole group. CONCLUSION:Terbinafine administered at a daily dose of 250 mg is an effective and well-tolerated option for the treatment of cutaneous sporotrichosis.
Authors: A Espinel-Ingroff; D P B Abreu; R Almeida-Paes; R S N Brilhante; A Chakrabarti; A Chowdhary; F Hagen; S Córdoba; G M Gonzalez; N P Govender; J Guarro; E M Johnson; S E Kidd; S A Pereira; A M Rodrigues; S Rozental; M W Szeszs; R Ballesté Alaniz; A Bonifaz; L X Bonfietti; L P Borba-Santos; J Capilla; A L Colombo; M Dolande; M G Isla; M S C Melhem; A C Mesa-Arango; M M E Oliveira; M M Panizo; Z Pires de Camargo; R M Zancope-Oliveira; J F Meis; J Turnidge Journal: Antimicrob Agents Chemother Date: 2017-09-22 Impact factor: 5.191
Authors: Paula Gonçalves Viana; Anna Barreto Fernandes Figueiredo; Isabella Dib Ferreira Gremião; Luisa Helena Monteiro de Miranda; Isabela Maria da Silva Antonio; Jéssica Sepulveda Boechat; Ana Caroline de Sá Machado; Manoel Marques Evangelista de Oliveira; Sandro Antonio Pereira Journal: Mycopathologia Date: 2017-12-08 Impact factor: 2.574
Authors: Rosane Orofino-Costa; Dayvison Francis Saraiva Freitas; Andréa Reis Bernardes-Engemann; Anderson Messias Rodrigues; Carolina Talhari; Claudia Elise Ferraz; John Verrinder Veasey; Leonardo Quintella; Maria Silvia Laborne Alves de Sousa; Rodrigo Vettorato; Rodrigo de Almeida-Paes; Priscila Marques de Macedo Journal: An Bras Dermatol Date: 2022-09-22 Impact factor: 2.113
Authors: George R Thompson; Thuy Le; Ariya Chindamporn; Carol A Kauffman; Ana Alastruey-Izquierdo; Neil M Ampel; David R Andes; Darius Armstrong-James; Olusola Ayanlowo; John W Baddley; Bridget M Barker; Leila Lopes Bezerra; Maria J Buitrago; Leili Chamani-Tabriz; Jasper F W Chan; Methee Chayakulkeeree; Oliver A Cornely; Cao Cunwei; Jean-Pierre Gangneux; Nelesh P Govender; Ferry Hagen; Mohammad T Hedayati; Tobias M Hohl; Grégory Jouvion; Chris Kenyon; Christopher C Kibbler; Nikolai Klimko; David C M Kong; Robert Krause; Low Lee Lee; Graeme Meintjes; Marisa H Miceli; Peter-Michael Rath; Andrej Spec; Flavio Queiroz-Telles; Ebrahim Variava; Paul E Verweij; Ilan S Schwartz; Alessandro C Pasqualotto Journal: Lancet Infect Dis Date: 2021-08-06 Impact factor: 71.421